Back to the main directory
Company Analysis / Equity
- Initiating Coverage by Zacks
- Progress on Product Sales, Gov't Contracts, Commercialization Plan by Zacks
- Q2 Results / Operational Plan Moving Forward by Zacks
- Q4 Results / Interest in CytoSorb Accelerating by Zacks
- YoY and Sequential Revenue Growth Continues. by Zacks
- 10-K Filed by Zacks
- CryoPort's Shippers Displayed on FedEx Website by Zacks
- DFFN: Animal Toxicology Testing of TSC Successfully Completed in Preparation of Phase 3 Clinical Trial; Uplist to the Nasdaq Complete… by Zacks
- DFFND: Results From Phase 1/2 Clinical Trial of TSC Show High Percentage of Tumor Regression in GBM Patients… by Zacks
- DMPI: Ready to advance VAL-083 to pivotal Phase II/III trial in 1H2016, pipeline will be expanded to include NSCLC and ovarian cancer Buy by Zacks
- DMPI: Ready to advance VAL-083 to pivotal Phase II/III trial in 2016, pipeline will be expanded to include NSCLC and ovarian cancer Buy by Zacks
- DMPI: Ready to advance VAL-083 to pivotal Phase III trial in 2016, pipeline will be expanded to include NSCLC and ovarian cancer by Zacks
- DMPI: Three new clinical trials to be initiated, Pipeline will be expanded to include NSCLC and ovarian cancer. by Zacks
- Q1 2012 Results by Zacks
- Q3 2012 Results. Customer Adoption Taking Longer by Zacks
- DMPI: Encouraging preliminary efficacy data reported at ASCO, Ready to advance VAL- 083 to pivotal Phase II/III trial in 2H2015, pipeline will be expanded to include NSCLC Buy by Zacks
- DMPI: New data of VAL-083 presented at ASCO, registrational trial expected to begin in 2H14 Outperform by Zacks
- DMPI: Ready to advance VAL-083 to pivotal Phase II/III trial for the treatment of glioblastoma in 2H2015, pipeline will be expanded to include NSCLC Buy by Zacks
- DMPI: Positive Interim Phase I/II Clinical data reported, balance sheet remains strong Upgrade to Outperform by Zacks
- DRRX: DUR-928 holds great potential for NASH/Kidney Injury, POSIDUR Phase III initiated, and Remoxy NDA filing in 1Q16----Buy by Zacks
- DRRX: DUR-928 on track to enter into Phase II studies, Posimir Phase III initiated, and Remoxy NDA filing in 1Q16----Buy by Zacks
- DRRX: POSIDUR Phase 3 To Start This Fall by Zacks
- DRRX: Pfizer Walks From REMOXY, Meanwhile We Wait For An Update On POSIDUR by Zacks
- DRRX: Remoxy approved expected in 2H16, DUR-928 on track to enter into Phase II studies, Posimir Phase III initiated by Zacks
- DRRX: Still Optimistic About Durect by Zacks
- PFE Agreement Could Be Meaningful by Zacks
- CTSO: Q1 Inline. Continue To Expect Accelerating Growth in 2H by Zacks
- Q2 Revenue In-Line, Cost-Cutting Benefits Bottom-Line by Zacks
- CTSO: Record Product Sales in Q4 But Even Bigger Plans for 2014 by Zacks
- YOY, Sequential Revenue Growth Streak Continues. by Zacks
- 10-K Filed. Results In-Line With Our Numbers by Zacks
- Cryoport June 2012 by Zacks
- DFFN: Initiating Coverage of Diffusion Pharmaceuticals: Lead Compound Entering Phase 3 Clinical Trial in Brain Cancer by Zacks
- DMPI: Pipeline will be expanded to include NSCLC and ovarian cancer while ready to advance VAL-083 to pivotal Phase III trial in 2016, by Zacks
- DMPI: Ready to advance VAL-083 to pivotal Phase II/III trial in 1H2016, pipeline will be expanded to include NSCLC and ovarian cancer Buy by Zacks
- DMPI: Ready to advance VAL-083 to pivotal Phase II/III trial in 2016, pipeline will be expanded to include NSCLC and ovarian cancer Buy by Zacks
- DMPI: Ready to advance VAL-083 to pivotal Phase III trial in 2016, pipeline will be expanded to include NSCLC and ovarian cancer Buy by Zacks
- Initiating at Outperform by Zacks
- Q2 2012 Results. Progression With Gaining New Customers by Zacks
- Clinical/commercial stage biopharmaceutical company with strong balance sheet, but pipeline is weak - initiating with Neutral by Zacks
- DMPI: High doses may enhance success rate of VAL-083 for the treatment of glioblastoma, registrational trial expected to begin in late 2014 or early 2015 Outperform by Zacks
- DMPI: Ready to advance VAL-083 to pivotal Phase II/III trial for the treatment of glioblastoma in 1H2015, pipeline will be expanded to include NSCLC Outperform by Zacks
- Balance sheet remains strong, but pipeline is limited by Zacks
- DRRX: DUR-928 Takes Center Stage As Durect Corp s Future Looks Bright by Zacks
- DRRX: DUR-928 on track to enter into Phase II studies, POSIDUR Phase III initiated, and Remoxy NDA filing in 1Q16----Buy by Zacks
- DRRX: DUR-928 on track to enter into Phase II studies, and holds great potential for long term growth by Zacks
- DRRX: POSIDUR Phase III to Start This Fall, Remoxy NDA filing in 1Q16, DUR-928 holds great potential for NASH/Kidney Injury... Buy by Zacks
- DRRX: Posidur FDA Meeting And Remoxy Update From Pfizer Expected Soon by Zacks
- DRRX: Remoxy approved expected in 2H16, DUR-928 on track to enter into Phase II studies, Posimir Phase III initiated by Zacks
- DRRX: Ten Reasons To Buy DURECT On The POSIDUR Rejection... by Zacks